<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916487</url>
  </required_header>
  <id_info>
    <org_study_id>Fructo001</org_study_id>
    <secondary_id>EUDRACT2008-005861-80</secondary_id>
    <nct_id>NCT00916487</nct_id>
  </id_info>
  <brief_title>Efficacy of Fructose Metabolizing Enzymatic Product in Fructose Malabsorption</brief_title>
  <official_title>Efficacy of Fructose Metabolizing Enzymatic Product Fructosin(R) in Patients With Fructose Malabsorption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sciotec Diagnostic Technologies GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Austrian Research Promotion Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sciotec Diagnostic Technologies GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the enzymatic product Frucosin(R) is able
      to degrade fructose in vivo in the small intestine of patients with known fructose
      malabsorption by measuring hydrogen in the expiratory air.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fructose malabsorption is a digestive disorder in which the uptake of fructose in the small
      intestine is deficient. This leads to an increase of the concentration of fructose in the
      large intestine after the intake of fructose-rich meals. The exzess fructose is then degraded
      by intestinal microbes into CO2, CH4, H2 and short chain fatty acids causing symptoms like
      bloating, diarrhea, flatulence or stomach pain.

      The clinical diagnosis requires a hydrogen breath test after challenge with fructose. After
      an oral challenge with fructose the emerging hydrogen is measured in the expiratory air. A
      fructose malabsorption is diagnosed if the hydrogen in the expiratory air reaches 20ppm or
      more.

      In the course of this study the participants will take 2 hydrogen breath tests. Before each
      of these tests the participants will take either the active treatment (Fructosin(R)) or a
      placebo. The active treatment should reduce the exhaled hydrogen indicating a reduced
      concentration of fructose in the large intestine after fructose metabolization by the verum.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>area under the curve (AUC) of the exhaled breath hydrogen in ppm*min</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptoms during and after the hydrogen breath test (abdominal pain, flatulence, nausea and diarrhea/constipation)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Fructose Malabsorption</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm of study in cross-over design</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fructosin</intervention_name>
    <description>Three capsules of Fructosin before one of the hydrogen breath tests.</description>
    <arm_group_label>Arm1</arm_group_label>
    <other_name>Frutosin(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed fructose malabsorption

        Exclusion Criteria:

          -  Gravidity

          -  diabetes mellitus

          -  recent gastrointestinal surgery

          -  recent endoscopy

          -  recent antibiotics therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Komericki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Pongracz, MS</last_name>
    <role>Study Director</role>
    <affiliation>Sciotec Diagnostic Technologies GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <last_update_submitted>December 17, 2010</last_update_submitted>
  <last_update_submitted_qc>December 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pongracz Christian</name_title>
    <organization>Sciotec Diagnostic Technologies GmbH</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malabsorption Syndromes</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 20, 2012</submitted>
    <returned>December 18, 2012</returned>
    <submitted>January 8, 2013</submitted>
    <returned>February 11, 2013</returned>
    <submitted>February 12, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

